Preparation process of umeclidinium bromide

Abstract

The present invention provides a process for preparing umeclidinium bromide in a single pure crystalline form that is suitable for industrialization, more efficient, and has a consistent level of crystallinity and chemical purity. The process involves reacting ethyl isonipecotate with 1-bromo-2-chloroethane to form ethyl 1-(2-chloroethyl)piperidine-4-carboxylate, which is then cyclized with lithium diisopropylamide to form ethyl 1-azabicyclo[2.2.2]octane-4-carboxylate, followed by recrystallization from 1-propanol or water to prepare umeclidinium bromide.

Description

[Technical Field]

[0001] The present invention relates to a novel preparation process for the compound 4-[hydroxyl(diphenyl)methyl]-1-[2-(phenylmethyl)oxy]ethyl]-1-azoniabicyclo[2.2.2]octane bromide, also known as umeclidinium bromide. [Background technology]

[0002] Umeclidinium bromide is an effective anticholinergic agent that has been used to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). It is used to prepare pharmaceutical compositions administered once daily in microgram doses as a dry powder for oral inhalation. Novel compositions, combinations, dosage forms (e.g., metered-dose inhalers), and dosages using umeclidinium bromide are being developed.

[0003] Umeclidinium bromide, the compound with the molecular structure (I) shown below, is a long-acting muscarinic antagonist used to treat airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

[0004] [ka] The synthesis of umeclidinium bromide claimed in International Publication No. 2005 / 104745 comprises the following four steps:

[0005] [ka] The important intermediate, ethyl 1-(2-chloroethyl)piperidine-4-carboxylate of formula (II), is synthesized by reacting 1-bromo-2-chloroethane with ethyl isonipecotate in acetone in the presence of potassium carbonate. However, the compound of formula (II) is prepared in very low yield (39%) due to the formation of the dimeric byproduct diethyl 1,1'-(ethane-1,2-diyl)bis(piperidine-4-carboxylate))(V), which must be separated from the primary compound by chromatographic techniques.

[0006] [ka] To overcome the dimerization problem and the resulting low yield, International Publication No. 2014 / 027045 claims an alternative two-step process for preparing the compound of formula (II) in a better yield (80%).

[0007] [ka] While there is no doubt that this synthetic alternative may yield better yields, the requirement of two reaction steps instead of the single step described in International Publication 2005 / 104745 is not the best solution for industrial applications. In addition, International Publication 2014 / 027045 discloses the use of high temperatures in the first step and the use of a highly corrosive and toxic reagent in the second step, namely thionyl chloride, which produces an environmentally undesirable SOx byproduct. These are three main disadvantages compared to the milder conditions described in International Publication 2005 / 104745.

[0008] Furthermore, International Publication No. 2016 / 071792 claims the following one-step process for preparing a compound of formula (II), which involves the reaction of ethyl isonipecotinate with halogenated acetaldehyde in a methanol:acetic acid mixture with a reducing agent added.

[0009] [ka] Although this synthesis yields a better yield (90%) compared to those described in International Publications 2005 / 104745 and 2014 / 027045, it requires the use of a methanol-soluble, aqueous, acidic solution that allows for some decomposition of the ester moiety prior to the reaction with the reducing agent.

[0010] International Publication No. 2011 / 029896 describes an alternative process for preparing umeclidinium bromide using different intermediates, as follows:

[0011] [ka] Here, P is a protecting group; R is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycle, aryl, and heteroaryl; X and Y are leaving groups, provided that X and Y are different.

[0012] However, this process involves a longer synthetic route and includes additional protection-deprotection steps, making it more complex than the process disclosed in WO 2005 / 104745.

[0013] The unsolvated crystalline form of umeclidinium bromide has been disclosed as a polymorph of the active pharmaceutical ingredient (WO 2014 / 027045, US 9,273,001), indicating that the compound can give rise to various solids with different physical properties. The preparation of pure umeclidinium bromide in single crystal form has been a challenge for the industry because umeclidinium bromide has a high sensitivity to forming solvates. Solvates of umeclidinium bromide include a methanol solvate (CZ27764 (Sanofi)), and ethanol, 2-propanol, 2-methylpropan-1-ol, chlorobenzene, and p-xylene solvates have been disclosed (WO 2014 / 027045, US 9,273,001). 1-Propanol is used as the solvent in the final process step to minimize solvate formation (US 9,273,001) and avoid the resuspension of the compound in ethyl acetate, methanol, and water that was previously required (example 84, Method B, WO 2005 / 104745).

Prior Art Documents

Patent Documents

[0014]

Patent Document 1

Patent Document 2

Patent Document 3

[0015] To meet the market demand for umeclidinium bromide, there is a need to develop more efficient processes, specifically those that offer advantages over those previously disclosed in International Publications 2016 / 071792, 2005 / 104745, 2014 / 027045, and 2011 / 029896. Furthermore, there is a need to provide a process for preparing a single, pure crystalline form of umeclidinium bromide with a certain level of crystallinity and chemical purity. [Means for solving the problem]

[0016] According to one aspect of the present invention, a process for preparing umeclidinium bromide is provided, the preparation process being: a) Reacting ethyl isonipecotinate with 1-bromo-2-chloroethane in a solvent in the presence of an organic base to form ethyl(II) 1-(2-chloroethyl)piperidine-4-carboxylate or a salt thereof; b) Reacting ethyl(II) 1-(2-chloroethyl)piperidine-4-carboxylate or a salt thereof with lithium diisopropylamide in a solvent to form ethyl(III) 1-azabicyclo[2.2.2]octane-4-carboxylate; c) The step of reacting 1-azabicyclo[2.2.2]octane-4-carboxylate ethyl(III) with phenyl lithium in a solvent to form 1-azabicyclo[2.2.2]octo-4-yl(diphenyl)methanol(IV); and d) The step of reacting 1-azabicyclo[2.2.2]octo-4-yl(diphenyl)methanol(IV) with ((2-bromoethoxy)methyl)benzene in a solvent to form umeclidinium bromide of 4-[hydroxyl(diphenyl)methyl]-1-[2-(phenylmethyl)oxy]ethyl]-1-azoniabicyclo[2.2.2]octane bromide(I).

[0017] According to another aspect of the present invention, a) A process is provided comprising the step of reacting ethyl isonipecotinate with 1-bromo-2-chloroethane in a solvent in the presence of an organic base to form ethyl(II) 1-(2-chloroethyl)piperidine-4-carboxylate or a salt thereof.

[0018] According to a further aspect of the present invention, d) A process is provided in which 1-azabicyclo[2.2.2]octo-4-yl(diphenyl)methanol is reacted with ((2-bromoethoxy)methyl)benzene in a solvent to form 4-[hydroxyl(diphenyl)methyl]-1-[2-(phenylmethyl)oxy]ethyl]-1-azoniabicyclo[2.2.2]octane bromide (I), umeclidinium bromide, wherein the solvent is selected from the group consisting of cyclic ethers such as tetrahydrofuran, aromatic solvents such as toluene, ketones such as acetone, and protic solvents such as water, or combinations thereof, and optionally the solvent is water.

[0019] Other aspects of the present invention relate to ethyl(II) 1-(2-chloroethyl)piperidine-4-carboxylate and umeclidinium bromide obtained by the process of the present invention, and to pharmaceutical compositions containing the umeclidinium bromide.

[0020] Surprisingly, step a) of the present invention has been found to supply the key intermediate 1-(2-chloroethyl)piperidine-4-carboxylate ethyl(II) in a higher yield (66%) than the process disclosed in International Publication No. 2005 / 104745, without requiring an increase in the number of steps (e.g., protection-deprotection steps), without the use of high temperatures, and without the use of undesirable reagents (e.g., corrosive reagents, toxic reagents, or methanol / aqueous acid systems). Step a) of the present invention controls the formation of undesirable byproducts such as diethyl 1,1'-(ethane-1,2-diyl)bis(piperidine-4-carboxylate)(V). The 1-(2-chloroethyl)piperidine-4-carboxylate ethyl(II) obtained during step a) of the present invention can be purified or used directly in subsequent process steps without purification (e.g., purification by chromatography). The process of the present invention enables telescoped (or one-pot) synthesis of umeclidinium bromide, where the starting materials undergo a continuous chemical reaction. Such synthesis is in high demand because it improves chemical reaction efficiency by avoiding the separation and purification of intermediates, and therefore increases chemical yield while saving time and resources.

[0021] One advantage of step a) of the present invention is that by using the 1-(2-chloroethyl)piperidine-4-carboxylate ethyl(II) intermediate obtained from this process step, a single pure crystalline form of umeclidinium bromide having a certain level of crystallinity and chemical purity can be prepared.

[0022] Furthermore, it has been found that step d) of the present invention provides a product having a single pure crystalline form with a certain level of crystallinity and chemical purity. Thus, one of the further advantages of the process of the present invention is that the umeclidinium bromide obtained during step d) of the present invention is a single pure crystalline form having a certain level of crystallinity and chemical purity.

[0023] Accordingly, the present invention discloses a preparation process for umeclidinium bromide that provides a single pure crystalline form having a certain level of crystallinity and chemical purity.

[0024] Finally, the process of the present invention enables the production of umeclidinium bromide having a particle size suitable for inhalation. [Brief explanation of the drawing]

[0025] [Figure 1] This is the XPRD diffraction pattern of umeclidinium bromide obtained from Example 18. [Figure 2] This is a DSC thermogram of umeclidinium bromide obtained from Example 18. [Figure 3] This is the TGA thermogram of umeclidinium bromide obtained from Example 18. [Figure 4] HPLC of umeclidinium bromide obtained from Example 18. [Figure 5] This is the HPLC of 1-azabicyclo[2.2.2]octo-4-yl(diphenyl)methanol(IV) obtained after the three steps of Example 19 and used as a starting material in the final step of preparing umeclidinium bromide. [Figure 6] Example 20 shows the HPLC of umeclidinium bromide recrystallized from water. [Figure 7] This is the XRPD of umeclidinium bromide before it was processed into microparticles. [Figure 8] Example 21 shows the XRPD of umeclidinium bromide after micronization using a fluid energy jet mill. [Figure 9] Example 22 shows the XRPD of umeclidinium bromide after high-pressure homogenization and micronization. [Modes for carrying out the invention]

[0026] The present invention provides an alternative process for preparing umeclidinium bromide and ethyl(II) 1-(2-chloroethyl)piperidine-4-carboxylate, which is an important intermediate in the preparation of umeclidinium bromide.

[0027] The present invention provides a process comprising the following steps. a) Reacting ethyl isonipecotinate with 1-bromo-2-chloroethane in a solvent in the presence of an organic base to form ethyl(II) 1-(2-chloroethyl)piperidine-4-carboxylate or a salt thereof; b) Reacting ethyl(II) 1-(2-chloroethyl)piperidine-4-carboxylate or a salt thereof with lithium diisopropylamide in a solvent to form ethyl(III) 1-azabicyclo[2.2.2]octane-4-carboxylate; c) Reacting ethyl(III) 1-azabicyclo[2.2.2]octane-4-carboxylate with lithium phenyl in a solvent to form 1-azabicyclo[2.2.2]octo-4-yl(diphenyl)methanol(IV); d) Reacting 1-azabicyclo[2.2.2]octo-4-yl(diphenyl)methanol(IV) with ((2-bromoethoxy)methyl)benzene in a solvent to form 4-[hydroxyl(diphenyl)methyl]-1-[2-(phenylmethyl)oxy]ethyl]-1-azoniabicyclo[2.2.2]octane bromide(I), umeclidinium bromide, which is a single pure crystalline form, and optionally; e) Recrystallizing umeclidinium bromide to obtain a consistently high-purity product, and optionally; f) A step of atomizing umeclidinium bromide while maintaining its crystalline form to obtain a product with a particle size suitable for inhalation.

[0028] Steps a) through e) can be combined in the absence of step f). Steps a) through d) and f) can be combined in the absence of step e).

[0029] Steps d) and e) can be combined in the absence of other process steps. Steps d) and f) can be combined in the absence of other process steps. Steps d), e) and f) can be combined in the absence of other process steps.

[0030] Step a) of the present invention can be carried out as follows: a) Ethyl isonipecotinate is reacted with 1-bromo-2-chloroethane in a solvent in the presence of an organic base at a temperature of about 20°C to about 56°C to form ethyl 1-(2-chloroethyl)piperidine-4-carboxylate(II); preferably thereafter (i) solvent exchange is carried out, preferably by water extraction to remove the salt formed from the reaction mixture, the resulting solution is concentrated, and ethyl 1-(2-chloroethyl)piperidine-4-carboxylate(II) present in the solution after filtration to remove the dimer is isolated; or thereafter; (ii) preferably by water extraction to remove any salt formed from the reaction mixture, the resulting solution is acidified with an inorganic or organic acid, preferably hydrochloric acid, acetic acid, succinic acid or oxalic acid, and preferably by filtration and drying to isolate the product ethyl 1-(2-chloroethyl)piperidine-4-carboxylate(II) as a salt.

[0031] The solvent used in step a) can be selected from the group consisting of ketones such as acetone.

[0032] The organic base used in step a) can be selected from a group of organic bases such as amines, including triethylamine, pyridine, N,N-diisopropylethylamine, 4-(dimethylamino)pyridine, and 1,8-diazabicyclo[5.4.0]undeca-7-ene. Preferably, the organic base is triethylamine. Once the reaction in step a) is complete, solvent exchange can be performed, the triethylamine salt can be removed by water extraction, and the resulting solution can be concentrated to isolate ethyl(II) 1-(2-chloroethyl)piperidine-4-carboxylate. By using triethylamine as the organic base, ethyl(II) 1-(2-chloroethyl)piperidine-4-carboxylate can be obtained in a yield of up to 66%, with a residual amount of diethyl 1,1'-(ethane-1,2-diyl)bis(piperidine-4-carboxylate)(V) of less than 14%. In contrast, according to the innovative procedure disclosed in International Publication No. 2005 / 104745, the production of the by-product diethyl 1,1'-(ethane-1,2-diyl)bis(piperidine-4-carboxylate)(V) reached 22%.

[0033] Step a) can be carried out at a temperature between about 20°C and about 56°C, preferably between about 20°C and about 30°C, and more preferably at a temperature between about 20°C and about 25°C. At temperatures above 30°C, a more significant amount of the by-product diethyl 1,1'-(ethane-1,2-diyl)bis(piperidine-4-carboxylate)(V) is obtained, and ethyl 1-(2-chloroethyl)piperidine-4-carboxylate(II) is produced in a lower yield (34%). Step a) can be carried out over a period of about 14 hours and about 24 hours.

[0034] After removing the salt (e.g., triethylamine salt) by water extraction, the resulting solution can be acidified with an inorganic or organic acid, preferably hydrochloric acid, acetic acid, succinic acid, or oxalic acid, or a solution thereof. The product, 1-(2-chloroethyl)piperidine-4-carboxylate ethyl(II), can then be isolated as a salt, preferably by filtration and drying.

[0035] As disclosed above, step a) may include exchanging the reaction solvent. The exchange solvent may contain one or more alkanes, such as n-heptane or a mixture of heptanes.

[0036] As disclosed above, step a) may also include removal of the dimer by filtration. The reaction mixture may be cooled before filtration, optionally cooled to -20°C and maintained at that temperature for about 12 to 24 hours, or optionally maintained for 16 hours.

[0037] In combination, step a) may include: i) Exchange of reaction solvent; ii) Aqueous extraction; and iii) Removal of dimers by filtration.

[0038] Step b) of the present invention can be carried out as follows. b) In a solvent, preferably at a temperature between about -50°C and about 25°C, ethyl 1-(2-chloroethyl)piperidine-4-carboxylate (II) or a salt thereof is reacted with lithium diisopropylamide to form ethyl 1-azabicyclo[2.2.2]octane-4-carboxylate (III) or a salt thereof; preferably thereafter, the salt is removed from the reaction mixture, preferably by basic water extraction, and then solvent distillation and solvent exchange are carried out.

[0039] The solvent used in step b) can be selected from the group consisting of cyclic ethers such as tetrahydrofuran (THF).

[0040] Step c) of the present invention may be carried out as follows: c) In a solvent, preferably at a temperature between about -30°C and about 25°C, ethyl(III) 1-azabicyclo[2.2.2]octane-4-carboxylate or a salt thereof is reacted with phenyllithium to form 1-azabicyclo[2.2.2]octo-4-yl(diphenyl)methanol(IV) or a salt thereof; preferably, the reaction mixture containing 1-azabicyclo[2.2.2]octo-4-yl(diphenyl)methanol(IV) or a salt thereof is treated with water, the resulting solution is concentrated, preferably then a suitable poor solvent is added to produce a precipitate, and preferably the product is isolated by filtration and drying to achieve a purity of 98% or higher by HPLC.

[0041] The solvent used in step c) can be selected from the group consisting of cyclic ethers such as THF.

[0042] Step d) of the present invention may be carried out as follows: d) In a solvent, at a temperature between approximately 40°C and the solvent reflux temperature, preferably between approximately 60°C and the solvent reflux temperature, 1-azabicyclo[2.2.2]octo-4-yl(diphenyl)methanol(IV) and ((2-bromoethoxy)methyl)benzene are reacted to form umeclidinium bromide of 4-[hydroxyl(diphenyl)methyl]-1-[2-(phenylmethyl)oxy]ethyl]-1-azoniabicyclo[2.2.2]octane bromide(I). The reaction mixture is then preferably cooled to a temperature between approximately -10°C and approximately 5°C, and the suspension is stirred at a temperature between approximately -10°C and approximately 5°C for approximately 2 hours. The obtained product is then preferably isolated by filtration and dried at a temperature between approximately 35°C and approximately 55°C, preferably under vacuum, to obtain a single-crystal product with a purity of 98% or higher as determined by HPLC.

[0043] The solvent used in step d) can be selected from the group consisting of cyclic ethers such as THF, aromatic solvents such as toluene, ketones such as acetone, and protic solvents such as water. Step d) can be carried out at a temperature between approximately 40°C and approximately 111°C, preferably optionally between approximately 60°C and approximately 100°C. Step d) can be carried out over a period of approximately 18 hours and approximately 24 hours. Once the reaction is complete, the reactants are cooled to obtain umeclidinium bromide in a maximum yield of 84%. The purity of the product obtained by the described procedure is typically 98.0% or higher in single crystal form, as measured by HPLC. The crystalline form of isolated umeclidinium bromide is the non-solvated form of umeclidinium bromide.

[0044] Step e) of the present invention may be carried out as follows: e) Recrystallize umeclidinium bromide in a solvent at a temperature between approximately 40°C and the solvent reflux temperature, preferably between approximately 60°C and approximately 80°C, to obtain umeclidinium bromide of 4-[hydroxyl(diphenyl)methyl]-1-[2-(phenylmethyl)oxy]ethyl]-1-azoniabicyclo[2.2.2]octane bromide (I). Preferably, the reaction mixture is cooled to a temperature between approximately -10°C and approximately 5°C, and the suspension is stirred at a temperature between approximately -10°C and approximately 5°C for approximately 2 hours. The obtained product is then preferably isolated by filtration and dried at a temperature between approximately 35°C and approximately 55°C, preferably under vacuum, to obtain a single-crystal product with a purity of 99% or higher as determined by HPLC.

[0045] Umeclidinium bromide obtained according to step d) of the present invention can be recrystallized. The recrystallization solvent can be selected from the group consisting of an alcohol such as 1-propanol, a protic solvent such as water, or a mixture of both types of solvents. Preferably, recrystallization is carried out in water by suspending the starting material in water at a temperature optionally between about 40°C and about the reflux temperature of the solvent, preferably between about 60°C and about 80°C. The resulting solution may be cooled to a temperature between about -10°C and about 5°C, and the resulting suspension may be stirred between about -10°C and about 5°C for about 2 hours. Preferably, umeclidinium bromide is isolated (optionally by filtration), washed with water (optional), and then dried. Umeclidinium bromide may be dried under vacuum at a temperature between about 35°C and about 55°C. The dried product typically has a purity of 99.0% or higher by HPLC and exhibits a single-crystal form.

[0046] Figures 1-9 show the X-ray powder diffraction (XRPD) diffraction pattern, differential scanning calorimetry (DSC) thermogram, thermogravimetric analysis (TGA) thermogram, and HPLC chromatogram of the product obtained according to the present invention.

[0047] The umeclidinium bromide obtained from the present invention is preferably atomized to obtain a material with a particle size suitable for inhalation. Therefore, the present invention also provides an atomization process for adjusting the particle size while maintaining the crystalline form of umeclidinium bromide.

[0048] The following embodiments are provided to illustrate the process of the present invention and are not intended to be construed as limitations of the invention. Minor modifications can be made without deviating from the spirit and scope of the invention.

[0049] <Example 1> Preparation of ethyl 1-(2-chloroethyl)-4-piperidine-4-carboxylate hydrochloride(II) Trimethylamine (1.09 mL, 7.79 mmol) was added to a solution of ethyl isonipecotinate (0.80 mL, 5.19 mmol) in acetone (7.20 mL), followed by the addition of 1-bromo-2-chloroethane (0.86 mL, 10.38 mmol). The reaction mixture was stirred at 25°C for 24 hours and then concentrated under vacuum. The resulting residue was treated with water (3.0 mL) and extracted with ethyl acetate (3 x 3.0 mL). The combined organic layer was dried over MgSO4, filtered, and concentrated under vacuum. The crude product was purified by flash chromatography on silica gel (gradient 1:1 n-hexane / ethyl acetate to 9:1 ethyl acetate / methanol) to obtain the desired compound (colorless liquid, 0.75 g, 65.6%) and their respective dimers (0.25 g, 14.0%).

[0050] 1-(2-chloroethyl)-4-piperidine-4-carboxylate ethyl(II): 1 H-NMR(300MHz,CDCl3)δ4.11(q,J=5.3Hz,2H),3.55(t,J=4.0Hz,2H),2.88-2.84(m,2H),2.68(t,J=4.0Hz, 2H),2.24(dt,J=12.0,3.0Hz,1H),2.12(td,J=11.3,2.7Hz,2H),1.93-1.65(m,4H),1.22(t,J=9.0Hz,3H); 13 C-NMR (75MHz, CDCl3) δ175.11,60.51,60.21,53.18,41.23,41.09,28.29,14.38. MS (mass spectrometry) (ESI, electrospray ionization) m / z (mass to charge ratio) C 10 H 18 Calculated value of ClNO2: 219, measured value: 220 [M+H] + .

[0051] Diethyl 1,1'-(ethane-1,2-diyl)bis(piperidine-4-carboxylate)(V): 11H-NMR(300 MHz, CDCl3) δ 4.11 (q, J = 5.25 Hz, 4H), 2.99 - 2.76 (m, 4H), 2.47 (s, 4H), 2.30 - 2.20 (m, 2H), 2.07 - 1.99 (m, 6H), 1.90 - 1.84 (m, 4H), 1.79 - 1.66 (m, 4H), 1.23 (t, J = 6.0 Hz, 6H); 13 13C-NMR(75 MHz, CDCl3) δ 175.29, 60.49, 56.43, 53.68, 41.29, 28.40, 14.40. MS (Mass spectrometry) (ESI, Electrospray ionization) m / z (Mass-to-charge ratio) C 18 H 32 Calculated value of C + H <实施例2>

[0052] <Example 2> Preparation of Ethyl 1-(2-chloroethyl)-4-piperidine-4-carboxylate (II) Trimethylamine (1.09 mL, 7.79 mmol) was added to a solution of ethyl isonipecotate (0.80 mL, 5.19 mmol) in acetone (8.60 mL), followed by the addition of 1-bromo-2-chloroethane (0.86 mL, 10.38 mmol). The reaction mixture was stirred at 25 °C for 17 h, then n-heptane (8.6 mL) was added and the acetone was removed under vacuum to a volume of 8.6 ml. Water (8.6 mL) was added to the mixture and it was extracted with n-heptane (2 x 8.6 mL). The combined organic layers were dried over MgSO4, filtered and concentrated under vacuum. Further n-heptane was added (2.40 mL) and the solution was left at 0 °C for 1 h and cooled to -20 °C over 16 h. The solution was filtered to remove the dimer diethyl 1,1'-(ethane-1,2-diyl)bis(piperidine-4-carboxylate) (V), and then concentrated under vacuum. Purification of the crude product was carried out by flash chromatography on silica gel (gradient from 1:1 n-hexane / ethyl acetate to 9:1 ethyl acetate / methanol), giving the desired compound (colorless liquid, 0.63 g, 55.1%) and the respective dimer (0.10 g, 5.8%).

[0053] <实施例3> <Example 3>Preparation of ethyl(II) 1-(2-chloroethyl)-4-piperidine-4-carboxylate A solution of ethyl isonipecotinate (0.40 mL, 2.60 mmol) and triethylamine (0.55 mL, 3.90 mmol) in acetone (1.3 mL) was slowly added to a solution of 1-bromo-2-chloroethane (0.43 mL, 5.19 mmol) in acetone (3.0 mL) over 5 hours at 56°C. The reaction mixture was stirred at 56°C for 24 hours and then concentrated under vacuum. The resulting residue was treated with water (1.0 mL) and extracted with diethyl ether (3 x 3.0 mL). The combined organic layer was dried over MgSO4, filtered, and concentrated under vacuum. The crude product was purified by flash chromatography on silica gel (6:4n-hexane / ethyl acetate) to obtain the desired compound (colorless liquid, 0.19 g, 33.5%) and its respective dimers.

[0054] <Example 4> Preparation of ethyl(II) 1-(2-chloroethyl)-4-piperidine-4-carboxylate A solution of ethyl isonipecotinate (0.40 mL, 2.60 mmol) and triethylamine (0.55 mL, 3.90 mmol) in acetone (1.6 mL) was slowly added over 5 hours at room temperature to a solution of 1-bromo-2-chloroethane (0.86 mL, 10.38 mmol) and potassium iodide (10%, 1.04 mmol, 0.17 mg) in acetone (7.0 mL). The reaction mixture was stirred at 25°C for 24 hours and then concentrated under vacuum. The resulting residue was treated with water (1.0 mL) and extracted with diethyl ether (3 x 3.0 mL). The combined organic layer was dried over MgSO4, filtered, and concentrated under vacuum. The crude product was purified by flash chromatography on silica gel (6:4n-hexane / ethyl acetate) to obtain the desired compound (colorless liquid, 0.29 g, 50.1%) and its respective dimers.

[0055] <Example 5> Preparation of ethyl(II) 1-(2-chloroethyl)-4-piperidine-4-carboxylate N,N-diisopropylethylamine (DIPEA) (1.36 mL, 7.79 mmol) was added to a solution of ethyl isonipecotinate (0.80 mL, 5.19 mmol) in acetone (8.60 mL), followed by the addition of 1-bromo-2-chloroethane (0.86 mL, 10.38 mmol). The reaction mixture was stirred at 25°C for 24 hours. Next, water (3.0 mL) was added, the pH was neutralized with HCl (1 M), and the aqueous phase was extracted with diethyl ether (3 x 10.0 mL). The combined organic layer was dried over MgSO4, filtered, and concentrated under vacuum. The crude product (0.67 g) was used. 1 Analysis by 1H-NMR revealed that the dimer was composed of ethyl(II) 1-(2-chloroethyl)-4-piperidine-4-carboxylate in a ratio of 1.00:0.06.

[0056] <Example 6> Preparation of ethyl(II) 1-(2-chloroethyl)-4-piperidine-4-carboxylate 4-dimethylaminopyridine (DMAP) (0.95 g, 7.79 mmol) was added to a solution of ethyl isonipecotinate (0.80 mL, 5.19 mmol) in acetone (8.60 mL), followed by the addition of 1-bromo-2-chloroethane (0.86 mL, 10.38 mmol). The reaction mixture was stirred at 25°C for 24 hours. Next, water (3.0 mL) was added, the pH was neutralized with HCl (1 M), and the aqueous phase was extracted with diethyl ether (3 x 10.0 mL). The combined organic layer was dried over MgSO4, filtered, and concentrated under vacuum. The crude product (0.52 g) was used. 1 Analysis by 1H-NMR revealed that the result was ethyl(II) 1-(2-chloroethyl)-4-piperidine-4-carboxylate in a ratio of 1.00:0.06 relative to the dimer.

[0057] <Example 7> Preparation of ethyl(II) 1-(2-chloroethyl)-4-piperidine-4-carboxylate 1,8-Diazabicycloundeca-7-ene (DBU) (1.16 mL, 7.79 mmol) was added to a solution of ethyl isonipecotinate (0.80 mL, 5.19 mmol) in acetone (8.60 mL), followed by the addition of 1-bromo-2-chloroethane (0.86 mL, 10.38 mmol). The reaction mixture was stirred at 25°C for 24 hours. Next, water (3.0 mL) was added, the pH was neutralized with HCl (1 M), and the aqueous phase was extracted with diethyl ether (3 x 10.0 mL). The combined organic layer was dried over MgSO4, filtered, and concentrated under vacuum. The crude product (0.88 g) was used. 1 Analysis by 1H-NMR did not detect any dimers.

[0058] <Example 8> Preparation of ethyl(II) 1-(2-chloroethyl)-4-piperidine-4-carboxylate Pyridine (0.63 mL, 7.79 mmol) was added to a solution of ethyl isonipecotinate (0.80 mL, 5.19 mmol) in acetone (8.60 mL), followed by the addition of 1-bromo-2-chloroethane (0.86 mL, 10.38 mmol). The reaction mixture was stirred at 25°C for 24 hours. Then n-heptane (8.6 mL) was added, and the acetone was removed under vacuum. To the resulting mixture, n-heptane (8.6 mL) was added again, and the acetone was removed again under vacuum to obtain a volume of 8.6 mL. Water (8.6 mL) was added to the mixture, and it was extracted with n-heptane (2 x 8.6 mL). The complexed organic layer was dried over MgSO4, filtered, and concentrated under vacuum. Crude product (0.38 g) 1 Analysis by 1H-NMR revealed that the result was ethyl(II) 1-(2-chloroethyl)-4-piperidine-4-carboxylate in a ratio of 1.00:0.10 relative to the dimer.

[0059] <Example 9> Preparation of 1-(2-chloroethyl)-4-piperidine-4-carboxylate ethyl hydrochloride To a solution of ethyl(II) 1-(2-chloroethyl)-4-piperidine-4-carboxylate (0.15 mL) in acetone (2 mL), hydrochloric acid (1.25 M) in ethanol (0.72 mL) was added dropwise at room temperature. The solvent was removed under vacuum to obtain a crystalline white solid.

[0060] <Example 10> Preparation of 1-azabicyclo[2.2.2]octane-4-carboxylate ethyl(III) A solution of ethyl(II) 1-(2-chloroethyl)-4-piperidine-4-carboxylate (5.0 g, 22.76 mmol) in tetrahydrofuran (THF, 147.0 mL) was cooled to -50°C under nitrogen. Lithium diisopropylamide (LDA) (2.0 M in heptane / THF / ethylbenzene, 17.0 mL, 34.0 mmol) was added to the solution over 25 minutes at -50°C. The reaction mixture was warmed to room temperature over 16 hours. The reaction was quenched with saturated aqueous K2CO3 solution (122.0 mL) and extracted with diethyl ether (3 x 120.0 mL). The combined organic layer was dried over MgSO4, filtered, and concentrated under vacuum. The resulting orange liquid was co-evaporated three times with dichloroethane to remove excess ethylbenzene and obtain an orange oil (4.15 g, 99.4%).

[0061] 1-Azabicyclo[2.2.2]octane-4-carboxylate ethyl(III): 1 H-NMR(300MHz, CDCl3) δ4.10(t,J=5.23Hz,2H),2.90-2.85(m,6H),1.71-1.66(m,6H),1.22(t,J=4.0Hz,3H). <Example 11> Preparation of 1-azabicyclo[2.2.2]octo-4-yl(diphenyl)methanol(IV) A phenyllithium solution (1.9 M, 22.30 mL, 42.40 mmol in 70 cyclohexane / 30 ether) was cooled to -30°C under nitrogen. A solution of 1-azabicyclo[2.2.2]octane-4-carboxylate ethyl(III) (2.0 g, 10.90 mmol) in THF (27.0 mL) was slowly added to the reaction mixture over 25 minutes at -30°C. The reaction mixture was warmed to room temperature over 16 hours. The reaction was quenched with water (10.0 mL) and then evaporated to dryness under vacuum. Water (40.0 mL) and ethyl acetate (40.0 mL) were added to precipitate (crash out) a white solid. This solid was filtered under vacuum to obtain a white powder (2.46 g, 76.8%).

[0062] 1-Azabicyclo[2.2.2]octo-4-yl(diphenyl)methanol(IV): 1 H-NMR (300MHz, CDCl3) δ7.54-7.51(m,3H),7.33-7.20(m,6H),2.85-2.80(m,6H),1.78-1.72(m,6H).MS(mass spectrometry)(ESI,electrospray ionization)m / z(mass-to-charge ratio)C 20 H 23 NO calculated value: 293, measured value: 294 [M+H] + <Example 12> Preparation of 4-[hydroxyl(diphenyl)methyl]-1-[2-(phenylmethyl)oxy]ethyl]-1-azoniabicyclo[2.2.2]octane bromide (I) To a solution of 1-azabicyclo[2.2.2]octo-4-yl(diphenyl)methanol (IV, 0.20 g, 0.69 mmol) in THF (30.0 mL), ((2-bromoethoxy)methyl)benzene (0.16 mL, 1.03 mmol) was added. The solution was stirred at 60°C for 24 hours. The solution was then cooled to 25°C and concentrated under vacuum to form a white solid. The product was filtered and washed under vacuum with ethyl acetate (5 x 20.0 mL) and n-hexane (5 x 20.0 mL). The white solid was then vacuum dried (0.30 g, 82.2%). 4-[hydroxyl(diphenyl)methyl]-1-[2-(phenylmethyl)oxy]ethyl]-1-azoniabicyclo[2.2.2]octane bromide (I): ¹H-NMR (300MHz, DMSO-d6) δ 7.54 (d, J=6.0Hz, 4H), 7.35-7.20 (m, 11H), 5.97 (s, 1H), 4.49 (s, 2H), 3.81 (b, 2H), 3.49-3.46 (m, 6H), 3.31 (s, 2H), 1.99 (bt, J=6.0Hz, 6H). MS (mass spectrometry) (ESI, electrospray ionization) m / z (mass-to-charge ratio) C 29 H 34 NO2 calculated value: 428, measured value: 428 [M+H]+ <Example 13> Preparation of 4-[hydroxyl(diphenyl)methyl]-1-[2-(phenylmethyl)oxy]ethyl]-1-azoniabicyclo[2.2.2]octane bromide (I) To a suspension of 1-azabicyclo[2.2.2]octo-4-yl(diphenyl)methanol (IV, 0.20 g, 0.69 mmol) in acetone (30.0 mL), ((2-bromoethoxy)methyl)benzene (0.16 mL, 1.03 mmol) was added. The reaction mixture was stirred at 60°C for 24 hours. The reaction solution was then cooled to 25°C and concentrated under vacuum to form a white solid. The product was filtered and washed under vacuum with ethyl acetate (5 x 20.0 mL) and n-hexane (5 x 20.0 mL). The white solid was then vacuum dried (0.27 g, 75.7%).

[0063] <Example 14> Preparation of 4-[hydroxyl(diphenyl)methyl]-1-[2-(phenylmethyl)oxy]ethyl]-1-azoniabicyclo[2.2.2]octane bromide (I) To a suspension of 1-azabicyclo[2.2.2]octo-4-yl(diphenyl)methanol (IV, 0.20 g, 0.69 mmol) in toluene (30.0 mL), ((2-bromoethoxy)methyl)benzene (0.16 mL, 1.03 mmol) was added. The reaction mixture was stirred at 60°C for 24 hours. The solution was then cooled to 25°C and concentrated under vacuum to form a white solid. The product was filtered and washed under vacuum with ethyl acetate (5 x 20.0 mL) and n-hexane (5 x 20.0 mL). The white solid was then vacuum dried (0.28 g, 79.6%).

[0064] <Example 15> Preparation of 4-[hydroxyl(diphenyl)methyl]-1-[2-(phenylmethyl)oxy]ethyl]-1-azoniabicyclo[2.2.2]octane bromide (I) To a suspension of 1-azabicyclo[2.2.2]octo-4-yl(diphenyl)methanol (IV, 0.20 g, 0.69 mmol) in toluene (30.0 mL), ((2-bromoethoxy)methyl)benzene (0.16 mL, 1.03 mmol) was added. The reaction mixture was stirred under reflux for 24 hours. The reaction mixture was then slowly cooled to a temperature between 2°C and 4°C, and a white solid precipitated. The product was filtered and washed under vacuum with ethyl acetate (5 x 20.0 mL) and n-hexane (5 x 20.0 mL). The white solid was then vacuum dried (0.28 g, 79.6%).

[0065] <Example 16> Preparation of 4-[hydroxyl(diphenyl)methyl]-1-[2-(phenylmethyl)oxy]ethyl]-1-azoniabicyclo[2.2.2]octane bromide (I) To a suspension of 1-azabicyclo[2.2.2]octo-4-yl(diphenyl)methanol (IV, 0.20 g, 0.69 mmol) in water (20.0 mL), ((2-bromoethoxy)methyl)benzene (0.16 mL, 1.03 mmol) was added. The reaction mixture was stirred under reflux for 24 hours. The reaction mixture was then slowly cooled to a temperature between 2°C and 4°C, and a white solid precipitated. The product was filtered and washed under vacuum with ethyl acetate (20.0 mL) and n-hexane (5 x 20.0 mL). The white solid was then vacuum dried (0.24 g, 68.3%).

[0066] <Example 17> Preparation of 4-[hydroxyl(diphenyl)methyl]-1-[2-(phenylmethyl)oxy]ethyl]-1-azoniabicyclo[2.2.2]octane bromide (I) To a suspension of 1-azabicyclo[2.2.2]octo-4-yl(diphenyl)methanol (IV, 0.20 g, 0.69 mmol) in water (15.0 mL) and acetone (15.0 mL), ((2-bromoethoxy)methyl)benzene (0.16 mL, 1.03 mmol) was added. The reaction mixture was stirred at 60°C for 24 hours. The reaction mixture was then slowly cooled to a temperature between 2°C and 4°C, and a white solid precipitated. The product was filtered and washed under vacuum with ethyl acetate (20.0 mL) and n-hexane (5 x 20.0 mL). The white solid was then vacuum dried (0.19 g, 54.2%).

[0067] <Example 18> Preparation of 4-[hydroxyl(diphenyl)methyl]-1-[2-(phenylmethyl)oxy]ethyl]-1-azoniabicyclo[2.2.2]octane bromide (I) To a suspension of 1-azabicyclo[2.2.2]octo-4-yl(diphenyl)methanol (IV, 0.75 g, 2.56 mmol) in water (112.50 mL), ((2-bromoethoxy)methyl)benzene (0.61 mL, 3.83 mmol) was added. The reaction mixture was stirred at 60 °C for 24 hours. The reaction mixture was then slowly cooled to a temperature between 2 °C and 4 °C and stirred at a temperature between 2 °C and 4 °C for 2 hours. The product was filtered and washed under vacuum with ethyl acetate (20.0 mL) and n-hexane (5 x 20.0 mL). The white solid was then vacuum dried (1.03 g, 78.9%).

[0068] <Example 19> Preparation of 4-[hydroxyl(diphenyl)methyl]-1-[2-(phenylmethyl)oxy]ethyl]-1-azoniabicyclo[2.2.2]octane bromide (I) Triethylamine (5.45 mL, 38.95 mmol) was added to a solution of ethyl isonipecotinate (4.0 mL, 25.95 mmol) in acetone (43.0 mL), followed by the addition of 1-bromo-2-chloroethane (4.32 mL, 52.14 mmol). The reaction mixture was stirred at 25°C for 17 hours. Then, n-heptane (43.0 mL) was added, and the acetone was removed under vacuum. To the resulting mixture, n-heptane (43.0 mL) was added again, and the acetone was further removed under vacuum to obtain a volume of 43.0 mL. Water (43.0 mL) was added to this mixture, and it was extracted with n-heptane (2 x 43.0 mL). The combined organic layer was dried over MgSO4, filtered, and concentrated under vacuum. This first crude product (4.02 g) was used. 1 Analysis by 1H-NMR yielded ethyl(II) 1-(2-chloroethyl)-4-piperidine-4-carboxylate in a ratio of 1.00:0.11 relative to the dimer. Furthermore, n-heptane (11.50 mL) was added to the crude product, and the solution was left at 0°C for 1 hour, followed by cooling at -20°C for 16 hours. The solid was filtered to remove the dimer, and then the solution of ethyl(II) 1-(2-chloroethyl)-4-piperidine-4-carboxylate was concentrated under vacuum. This second crude product (3.57 g) was then... 1Analysis by 1H-NMR yielded ethyl(II) 1-(2-chloroethyl)-4-piperidine-4-carboxylate in a ratio of 1.00:0.09 relative to the dimer.

[0069] The second crude product, 1-(2-chloroethyl)-4-piperidine-4-carboxylate ethyl(II) (3.57 g), was dissolved in THF (89.6 mL) and cooled to -50°C under nitrogen. LDA (1.0 M, 20.72 mL, 20.72 mmol in hexane / THF) was added to the solution over 25 minutes at -50°C. The reaction mixture was warmed to room temperature over 16 hours. The reaction was quenched with a saturated aqueous solution of K2CO3 (74.4 mL) and extracted with ethyl acetate (3 x 74.4 mL). The combined organic layer was dried over MgSO4, filtered, and concentrated under vacuum to obtain crude 1-azabicyclo[2.2.2]octane-4-carboxylate ethyl(III) (3.02 g) as an orange oil.

[0070] A solution of lithium phenyl (1.9 M, 33.7 mL, 64.1 mmol in 70 cyclohexane / 30 ether) was cooled to -30°C under nitrogen. A solution of crude 1-azabicyclo[2.2.2]octane-4-carboxylate ethyl(III) (3.02 g) in THF (36.7 mL) was slowly added to the reaction mixture over 25 minutes at -30°C. The reaction mixture was warmed to room temperature over 16 hours. The reaction was quenched with water (15 mL) and then evaporated to dryness under vacuum (result: yellow solid). When water (60.2 mL) and ethyl acetate (60.2 mL) were added, a white solid precipitated. This solid was filtered under vacuum to obtain crude 1-azabicyclo[2.2.2]octo-4-yl(diphenyl)methanol(IV) (1.76 g, 3-step yield: 23.0%) as a white powder.

[0071] Crude 1-azabicyclo[2.2.2]octo-4-yl(diphenyl)methanol(IV) (1.76 g, 5.83 mmol) was suspended in water (258.0 mL) and ((2-bromoethoxy)methyl)benzene (1.40 mL, 9.01 mmol) was added. The reaction mixture was stirred under reflux for 24 hours. The reaction mixture was then slowly cooled to a temperature between 2°C and 4°C and stirred at a temperature between 2°C and 4°C for 2 hours. The product was filtered under vacuum, and excess bromide was washed and removed with a compound with heptane (20.0 mL). The white solid was then vacuum dried (2.55 g, 84.0% yield of the final step).

[0072] <Example 20> Recrystallization of 4-[hydroxyl(diphenyl)methyl]-1-[2-(phenylmethyl)oxy]ethyl]-1-azoniabicyclo[2.2.2]octane bromide (I) A suspension of 4-[hydroxyl(diphenyl)methyl]-1-[2-(phenylmethyl)oxy]ethyl]-1-azoniabicyclo[2.2.2]octane bromide (I) (0.20 g) in water (2.25 mL) was heated to 80°C. The solution was stirred for 1 hour, then slowly cooled to a temperature between 2°C and 4°C, and stirred at a temperature between 2°C and 4°C for 2 hours. The solid was filtered and dried under vacuum (0.185 g, 92.5%).

[0073] <Example 21> Micronization of 4-[hydroxyl(diphenyl)methyl]-1-[2-(phenylmethyl)oxy]ethyl]-1-azoniabicyclo[2.2.2]octane bromide (I) 4-[hydroxyl(diphenyl)methyl]-1-[2-(phenylmethyl)oxy]ethyl]-1-azoniabicyclo[2.2.2]octane bromide (I) (3.0 g) was supplied to a fluid energy jet mill at a rate of 10 g / hour. The venturi was operated at a pressure of 4 bar and the ring at 3 bar with N2.

[0074] The isolated product showed the same XRPD as that of the starting material having a particle size distribution of Dv10 = 0.664 μm; Dv50 = 3.071 μm; Dv90 = 7.013 μm; span = 2.07, as shown in Figure 8.

[0075] <Example 22> Micronization of 4-[hydroxy(diphenyl)methyl]-1-[2-(phenylmethyl)oxy]ethyl]-1-azonia-bicyclo[2.2.2]octane bromide (I) 4-[hydroxy(diphenyl)methyl]-1-[2-(phenylmethyl)oxy]ethyl]-1-azonia-bicyclo[2.2.2]octane bromide (I) (15.0 g) was suspended in water (285.0 g) and stirred until a homogeneous suspension was obtained. The homogeneous suspension was fed to a laboratory-scale high-pressure homogenizer operated for a total of 100 cycles at a pressure of 60 bar. After the homogenization step, the suspension was transferred to a holding vessel. The homogenized suspension was fed to a laboratory-scale spray dryer while stirring at a feed rate of 5.7 ml / min and a drying temperature of 75 °C (T out).

[0076] The isolated product showed the same XRPD as that of the starting material having a particle size distribution of Dv10 = 0.55 μm; Dv50 = 2.10 μm; Dv90 = 4.77 μm; span = 2.03, as shown in Figure 9.

[0077] [Instrument parameters] <NMR - Nuclear Magnetic Resonance> 1 H and 13 C-NMR spectra were recorded on a Bruker 300 Avance at 300 MHz ( 1 H-NMR) and 75 MHz ( 13 C-NMR).

[0078] The MS experiment was carried out on a Micromass® Quattro Micro triple quadrupole (Waters®, Ireland) with electrospray in positive ion mode (ESI+), an ion source at 120 °C, a capillary voltage of 3.0 kV and a source voltage of 30 V.

[0079] <HPLC - High Performance Liquid Chromatography> The HPLC analysis was performed using a Waters® model Alliance / 2695 and 2487 detector (dual λ) system under the following conditions: Column: waters symmetry shield® RP18 4.6x150mm 3.5 micron Flow rate: 0.8 mL / min Injection volume: 10 uL Temperature: 30 °C Solvent A: H2O (0.1% TFA) Solvent B: CH3CN The gradient elution method was as follows:

[0080]

Table 1

[0081] <DSC - Differential Scanning Calorimetry> The DSC experiment was carried out on a DSC Q200 with a ramp of 10 °C / min up to 350 °C.

[0082] <TGA - Thermogravimetric Analysis> The TGA experiment was carried out on a TGA Q500 with a ramp of 10 °C / min up to 350 °C.

Claims

1. d) A process for preparing umeclidinium bromide, comprising reacting 1-azabicyclo[2.2.2]octo-4-yl(diphenyl)methanol with ((2-bromoethoxy)methyl)benzene in a solvent to form umeclidinium bromide of 4-[hydroxyl(diphenyl)methyl]-1-[2-(phenylmethyl)oxy]ethyl]-1-azoniabicyclo[2.2.2]octane bromide (I), wherein the solvent is selected from tetrahydrofuran, toluene, acetone, and water.

2. The process for preparing umeclidinium bromide according to claim 1, wherein the reaction in step d) is carried out at a temperature between 40°C and 111°C, optionally between 60°C and 100°C.

3. A process for preparing umeclidinium bromide according to claim 1, wherein after a portion of the umeclidinium bromide formed in step d) precipitates from the reaction mixture in step d), the reaction mixture in step d) is cooled to a temperature between -10°C and 10°C, optionally between 0°C and 5°C, so that the umeclidinium bromide formed in step d) further precipitates from the reaction mixture in step d).

4. The process for preparing umeclidinium bromide according to claim 3, wherein the precipitated umeclidinium bromide is filtered and dried to isolate a product with a purity of 98.0% or higher by HPLC, and the crystalline form of the optionally isolated umeclidinium bromide is the non-solvated form of umeclidinium bromide.

5. a) Reacting ethyl isonipecotinate with 1-bromo-2-chloroethane in a solvent at a temperature of 30°C or below, in the presence of an organic base, to form ethyl(II) 1-(2-chloroethyl)piperidine-4-carboxylate or a salt thereof; b) Reacting 1-(2-chloroethyl)piperidine-4-carboxylate ethyl(II) or a salt thereof with lithium diisopropylamide in a solvent to form 1-azabicyclo[2.2.2]octane-4-carboxylate ethyl(III); c) Reacting ethyl 1-azabicyclo[2.2.2]octane-4-carboxylate (III) with phenyllithium in a solvent to form 1-azabicyclo[2.2.2]octo-4-yl(diphenyl)methanol (IV). A process for preparing umeclidinium bromide according to any one of claims 1 to 4, further comprising:

6. The process for preparing umeclidinium bromide according to claim 5, wherein the organic base used in step a) is selected from the group consisting of 1,8-diazabicyclo[5.4.0]undeca-7-ene, triethylamine, pyridine, N,N-diisopropylethylamine, and 4-(dimethylamino)pyridine.

7. The process for preparing umeclidinium bromide according to claim 5, wherein the solvent in step a) comprises a ketone, and optionally the ketone is acetone.

8. The process for preparing umeclidinium bromide according to claim 5, wherein the salt in step a) is selected from the group consisting of hydrochloride, acetate, succinate, or oxalate.

9. The process for preparing umeclidinium bromide according to claim 5, wherein the reaction in step a) is carried out at a temperature between 20°C and 30°C, or between 20°C and 25°C.

10. The process for preparing umeclidinium bromide according to claim 5, further comprising step a) replacement of the reaction solvent.

11. The process for preparing umeclidinium bromide according to claim 10, wherein the exchange solvent comprises one or more alkanes, and optionally the exchange solvent comprises n-heptane or a mixture of heptanes.

12. The process for preparing umeclidinium bromide according to claim 5, further comprising step a) water extraction.

13. The process for preparing plumeclidinium bromide according to claim 12, wherein the water extraction comprises acidification with an inorganic or organic acid, and optionally the water extraction comprises acidification with hydrochloric acid, acetic acid, succinic acid, or oxalic acid.

14. The process for preparing umeclidinium bromide according to claim 5, wherein in step a), the reaction mixture is cooled to -20°C and maintained for 12 to 24 hours, optionally 16 hours.

15. e) The process for preparing umeclidinium bromide according to claim 5, further comprising the step of recrystallizing umeclidinium bromide in a solvent.

16. The process for preparing umeclidinium bromide according to claim 15, wherein umeclidinium bromide is recrystallized from a solvent selected from the group consisting of an alcohol and a protic solvent or a mixture of an alcohol and a protic solvent, and optionally umeclidinium bromide is recrystallized from 1-propanol, or umeclidinium bromide is recrystallized from water.

17. The process for preparing umeclidinium bromide according to claim 16, wherein umeclidinium bromide is recrystallized from water to obtain a product with a purity of 99.0% or higher by HPLC.

18. The process for preparing umeclidinium bromide according to claim 15, wherein the recrystallized product is isolated and dried by conventional drying techniques.

19. f) The process for preparing umeclidinium bromide according to claim 5, further comprising the step of atomizing umeclidinium bromide.

20. The process for preparing umeclidinium bromide according to claim 19, wherein the particle size is brought about by cavitation and / or interparticle collisions and / or shear stress in a grinding device.

21. A process for preparing umeclidinium bromide according to claim 19, further comprising the step of isolating umeclidinium bromide in powder form, optionally by spray drying.

Images